X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (142) 142
index medicus (95) 95
hematology (88) 88
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (80) 80
imatinib mesylate (67) 67
human necessities (65) 65
hygiene (65) 65
male (65) 65
medical or veterinary science (65) 65
preparations for medical, dental, or toilet purposes (65) 65
female (63) 63
specific therapeutic activity of chemical compounds ormedicinal preparations (62) 62
chemistry (61) 61
metallurgy (61) 61
middle aged (58) 58
chronic myeloid leukemia (57) 57
oncology (57) 57
adult (55) 55
chronic myelogenous leukemia (55) 55
organic chemistry (55) 55
aged (54) 54
benzamides (47) 47
investigating or analysing materials by determining theirchemical or physical properties (47) 47
measuring (47) 47
physics (47) 47
testing (47) 47
leukemia, myelogenous, chronic, bcr-abl positive - genetics (45) 45
leukemia (42) 42
chronic myeloid-leukemia (41) 41
imatinib (40) 40
pyrimidines - therapeutic use (38) 38
antineoplastic agents - therapeutic use (34) 34
piperazines - therapeutic use (33) 33
heterocyclic compounds (32) 32
leukemia, myelogenous, chronic, bcr-abl positive - pathology (32) 32
beer (29) 29
biochemistry (29) 29
compositions or test papers therefor (29) 29
condition-responsive control in microbiological orenzymological processes (29) 29
enzymology (29) 29
measuring or testing processes involving enzymes, nucleicacids or microorganisms (29) 29
microbiology (29) 29
mutation or genetic engineering (29) 29
processes of preparing such compositions (29) 29
spirits (29) 29
vinegar (29) 29
wine (29) 29
fusion proteins, bcr-abl - genetics (28) 28
treatment outcome (28) 28
aged, 80 and over (27) 27
cancer (27) 27
pyrimidines - administration & dosage (27) 27
tyrosine (26) 26
therapy (25) 25
compositions thereof (24) 24
culture media (24) 24
microorganisms or enzymes (24) 24
piperazines - administration & dosage (24) 24
propagating, preserving or maintaining microorganisms (24) 24
protein kinase inhibitors - therapeutic use (24) 24
hemic and lymphatic diseases (23) 23
cml (22) 22
antineoplastic agents - administration & dosage (21) 21
dasatinib (21) 21
derivatives thereof (21) 21
nucleic acids (21) 21
nucleosides (21) 21
nucleotides (21) 21
pyrimidines - pharmacology (21) 21
sugars (21) 21
tyrosine kinase inhibitors (21) 21
nilotinib (20) 20
antineoplastic agents (19) 19
follow-up (19) 19
abridged index medicus (18) 18
analysis (18) 18
antineoplastic agents - pharmacology (18) 18
k562 cells (18) 18
leukemia, myelogenous, chronic, bcr-abl positive - mortality (18) 18
life sciences (18) 18
bcr-abl (17) 17
drug resistance, neoplasm (17) 17
piperazines - pharmacology (17) 17
animals (16) 16
apoptosis (16) 16
mutation (16) 16
protein-tyrosine kinase (16) 16
protein-tyrosine kinases - antagonists & inhibitors (16) 16
disease-free survival (15) 15
fusion proteins, bcr-abl - metabolism (15) 15
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (15) 15
medical and health sciences (15) 15
medicin och hälsovetenskap (15) 15
mice (15) 15
remission induction (15) 15
resistance (15) 15
antimitotic agents (14) 14
cell line, tumor (14) 14
interferon-alpha (14) 14
protein kinase inhibitors - administration & dosage (14) 14
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (396) 396
French (62) 62
German (27) 27
Portuguese (5) 5
Spanish (5) 5
Danish (3) 3
Greek (3) 3
Chinese (2) 2
Italian (2) 2
Croatian (1) 1
Norwegian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of internal medicine, ISSN 0003-4819, 10/2018, Volume 169, Issue 7, p. 510
Journal Article
Best Practice & Research: Clinical Haematology, ISSN 1521-6926, 2016
Abstract Stopping tyrosine kinase inhibitor (TKI) therapy after achieving a sustained deep molecular response is an emerging treatment goal for patients with... 
Hematology, Oncology and Palliative Medicine
Journal Article
Journal Article
Hematology, ISSN 1520-4391, 12/2012, Volume 2012, Issue 1, pp. 122 - 128
Abstract After more than a decade of treatment of chronic myeloid leukemia (CML) patients with the BCR-ABL tyrosine kinase inhibitor imatinib, and despite the... 
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 10/2018, Volume 169, Issue 7, pp. 510 - 510
Journal Article
Blood, ISSN 0006-4971, 08/2013, Volume 122, Issue 6, pp. 872 - 884
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2017, Volume 35, Issue 3, pp. 298 - 305
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 11, pp. 1029 - 1035
Journal Article
British Journal of Haematology, ISSN 0007-1048, 01/2018, Volume 180, Issue 1, pp. 24 - 32
Journal Article
Blood, ISSN 0006-4971, 02/2017, Volume 129, Issue 7, pp. 846 - 854
Journal Article
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 04/2011, Volume 103, Issue 7, pp. 553 - 561
Imatinib slows development of chronic myeloid leukemia (CML). However, available information on morbidity and mortality is largely based on sponsored trials,... 
Piperazines - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Time Factors | Antineoplastic Agents - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Polymerase Chain Reaction | Adult | Female | Odds Ratio | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Drug Administration Schedule | Pyrimidines - administration & dosage | Kaplan-Meier Estimate | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Benzamides | MESYLATE | RESPONSES | INTERFERON | THERAPY | ONCOLOGY | SAFETY | RESISTANCE | FOLLOW-UP | PATIENTS RECEIVING IMATINIB | Development and progression | Care and treatment | Chronic myeloid leukemia | Research | Drug therapy | Patient outcomes | Edema | Imatinib | Statistical analysis | Mortality | Sex | Clinical trials | Diarrhea | Muscles | Survival | Morbidity | Hemopoiesis | Philadelphia chromosome | Tendons | Polymerase chain reaction | Side effects | Asthenia | Remission | Ligaments | Index Medicus
Journal Article